Charalampos Skarlis1, Maria Gontika1, Serafeim Katsavos1, Giorgios Velonakis2, Panagiotis Toulas2, Maria Anagnostouli3,4. 1. Immunogenetics Laboratory, 1st Department of Neurology, Medical School of National and Kapodistrian University of Athens, Aeginition Hospital, Athens, Greece. 2. Research Unit of Radiology and Medical Imaging, 2nd Department of Radiology, Medical School of National and Kapodistrian University of Athens, Eugenidion Hospital, Athens, Greece. 3. Immunogenetics Laboratory, 1st Department of Neurology, Medical School of National and Kapodistrian University of Athens, Aeginition Hospital, Athens, Greece managnost@med.uoa.gr. 4. Outpatient Section of Demyelinating Diseases Clinic, 1st Department of Neurology, Medical School of National and Kapodistrian University of Athens, Aeginition Hospital, Athens, Greece.
Abstract
BACKGROUND: The comorbidity between Multiple Sclerosis (MS) and Human Immunodeficiency Virus (HIV) infection is particularly rare. Only a few cases of comorbidity of Clinically Definite(CD)-MS and HIV have been documented worldwide, while the potential beneficial role of antiretroviral therapy regarding MS activity has long been an area of debate. CASE REPORT: We present a 36-year old male, bearing a diagnosis of CD-MS for twelve years. He had been treated for ten years with interferon-beta-1b, when he voluntarily discontinued therapy, claiming clinical stability. One year later he was diagnosed positive for HIV and he started and continued only on efavirenz/emricitabine/tenofovir-disoproxil fumarate (ATRIPLA®), remaining relapse-free until today. CONCLUSION: This fact, in combination with the unique pharmaceutical composition of the drug, which contains a component similar to a newly-approved agent for MS, dimethyl fumarate, prompted us to review the literature regarding this rare comorbidity and to suggest that the role of the antiretroviral therapy should be further explored in MS. Copyright
BACKGROUND: The comorbidity between Multiple Sclerosis (MS) and Human Immunodeficiency Virus (HIV) infection is particularly rare. Only a few cases of comorbidity of Clinically Definite(CD)-MS and HIV have been documented worldwide, while the potential beneficial role of antiretroviral therapy regarding MS activity has long been an area of debate. CASE REPORT: We present a 36-year old male, bearing a diagnosis of CD-MS for twelve years. He had been treated for ten years with interferon-beta-1b, when he voluntarily discontinued therapy, claiming clinical stability. One year later he was diagnosed positive for HIV and he started and continued only on efavirenz/emricitabine/tenofovir-disoproxil fumarate (ATRIPLA®), remaining relapse-free until today. CONCLUSION: This fact, in combination with the unique pharmaceutical composition of the drug, which contains a component similar to a newly-approved agent for MS, dimethyl fumarate, prompted us to review the literature regarding this rare comorbidity and to suggest that the role of the antiretroviral therapy should be further explored in MS. Copyright
Authors: Anne Wierinckx; John Brevé; Dominique Mercier; Marianne Schultzberg; Benjamin Drukarch; Anne-Marie Van Dam Journal: J Neuroimmunol Date: 2005-09 Impact factor: 3.478
Authors: Peter W Hunt; Jason Brenchley; Elizabeth Sinclair; Joseph M McCune; Michelle Roland; Kimberly Page-Shafer; Priscilla Hsue; Brinda Emu; Melissa Krone; Harry Lampiris; Daniel Douek; Jeffrey N Martin; Steven G Deeks Journal: J Infect Dis Date: 2008-01-01 Impact factor: 5.226
Authors: Daniel E Kaufmann; Daniel G Kavanagh; Florencia Pereyra; John J Zaunders; Elizabeth W Mackey; Toshiyuki Miura; Sarah Palmer; Mark Brockman; Almas Rathod; Alicja Piechocka-Trocha; Brett Baker; Baogong Zhu; Sylvie Le Gall; Michael T Waring; Ryan Ahern; Kristin Moss; Anthony D Kelleher; John M Coffin; Gordon J Freeman; Eric S Rosenberg; Bruce D Walker Journal: Nat Immunol Date: 2007-09-30 Impact factor: 25.606
Authors: W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky Journal: Ann Neurol Date: 2001-07 Impact factor: 10.422